Chinjune Lin

Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer.

J. Wang, H. Hsu, R. Lai, 2002, Japanese journal of clinical oncology.

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: A Clinical Trial

W. Gradishar, F. Cardoso, Joon Jeong, 2018, JAMA oncology.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

C. Porta, A. Ravaud, R. Figlin, 2016, Clinical genitourinary cancer.

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study

C. Tzeng, Jih-Luh Tang, Tsai-Yun Chen, 2018, Therapeutic advances in hematology.

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.

W. Gradishar, F. Cardoso, Joon Jeong, 2017 .

An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed.

Billy Amzal, Zhimei Liu, E. Calvo, 2015, Clinical therapeutics.

A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).

A. Ravaud, Yulei N. Wang, M. Shi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.